Literature DB >> 11524719

Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies.

D Steinke1, P Davey.   

Abstract

The reported association between antibiotic prescribing and resistance may be subject to bias or confounding. Bias describes any effect at any stage of investigation or inference tending to produce results that depart systematically from the true value. A confounding variable is one that is associated independently with both exposure and outcome. Confounding variables may create an apparent association or mask a real association. Pharmacoepidemiology is the study of the use and the effects of drugs in large numbers of people. We have used standard pharmacoepidemiological methods to investigate sources of bias and confounding in the association between prescribing and resistance. We conclude that the association is statistically valid and that the consistency of evidence supports a cause-effect relationship. Nonetheless, several important sources of bias and confounding must be taken into account in future studies that analyze the impact of prescribing policies on resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524719     DOI: 10.1086/321848

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Knowledge, attitudes and behavior regarding antibiotics use and misuse among adults in the community of Jordan. A pilot study.

Authors:  Mayadah Shehadeh; Ghadeer Suaifan; Rula M Darwish; Mayyada Wazaify; Luna Zaru; Suzan Alja'fari
Journal:  Saudi Pharm J       Date:  2011-12-02       Impact factor: 4.330

2.  Patterns of antibacterial use and impact of age, race/ethnicity, and geographic region on antibacterial use in an outpatient medicaid cohort.

Authors:  Alice M Gahbauer; Marco L Gonzales; B Joseph Guglielmo
Journal:  Pharmacotherapy       Date:  2014-04-19       Impact factor: 4.705

3.  Inhibition of propionibacterium acnes by bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius.

Authors:  Whitney P Bowe; Jennifer C Filip; Joseph M DiRienzo; Alla Volgina; David J Margolis
Journal:  J Drugs Dermatol       Date:  2006-10       Impact factor: 2.114

4.  Problems of basing patient recruitment for primary care studies on routine laboratory submissions.

Authors:  Cliodna McNulty; Michael Thomas; Rhiannon John; Andrew Lovering; Deirdre Lewis; Alasdair MacGowan
Journal:  J Clin Pathol       Date:  2007-03-02       Impact factor: 3.411

Review 5.  Short-course therapy for community-acquired pneumonia in paediatric patients.

Authors:  Shamim Qazi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model.

Authors:  Inga Odenholt; Ingegerd Gustafsson; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Knowledge and misconceptions regarding upper respiratory infections and influenza among urban Hispanic households: need for targeted messaging.

Authors:  Elaine Larson; Yu-Hui Ferng; Jennifer Wong; Maria Alvarez-Cid; Angela Barrett; Maria J Gonzalez; Shuang Wang; Stephen S Morse
Journal:  J Immigr Minor Health       Date:  2008-05-28

9.  Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data.

Authors:  P T Donnan; L Wei; D T Steinke; G Phillips; R Clarke; A Noone; F M Sullivan; T M MacDonald; P G Davey
Journal:  BMJ       Date:  2004-05-29

10.  Antimicrobial drugs in the home, United Kingdom.

Authors:  Cliodna A M McNulty; Paul Boyle; Tom Nichols; Douglas P Clappison; Peter Davey
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.